December 14, 2017
Via EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Mail Stop 4546
Washington, D.C. 20549
Attn: Jim B. Rosenberg, Mark Brunhofer and Sharon Blume, Office of Healthcare & Insurance
Re: AMAG Pharmaceuticals, Inc.
Form 10-K for the Fiscal Year Ended December 31, 2016
Filed February 21, 2017
Form 10-Q for the Quarterly Period Ended September 30, 2017
Filed November 6, 2017
File No. 001-10865
Dear Mr. Rosenberg, Mr. Brunhofer and Ms. Blume:
On behalf of AMAG Pharmaceuticals, Inc. (the Company), the Company hereby advises the staff (the Staff) of the Securities and Exchange Commission (the Commission) that the Company has received the Staffs letter dated December 13, 2017 (the Comment Letter), regarding the Commissions review of the Companys Annual Report on Form 10-K for the fiscal year ended December 31, 2016 and the Companys Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2017. The Company respectfully requests an extension until January 12, 2018 to respond to the Comment Letter in order to provide sufficient time for the Company to prepare the response. The Company is committed to responding to the Comment Letter promptly and intends to provide a response to the Staff no later than January 12, 2018. Should you have any questions regarding the request made herein, please do not hesitate to contact me at (617) 570-1762. Thank you very much for your courtesy and cooperation in this matter.
|
Sincerely, |
|
|
|
/s/ Jacqueline Mercier |
|
Jacqueline Mercier, Esq. |
|
Goodwin Procter LLP |
cc: Edward Myles, AMAG Pharmaceuticals, Inc.
Joseph D. Vittiglio, AMAG Pharmaceuticals, Inc.
Ettore A. Santucci, Goodwin Procter LLP